![Sue Smith](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Sue Smith formerly worked at EUSA Pharma, Inc., as Head-Oncology Marketing, Interlink Healthcare Communications, as Vice President, Kyowa Kirin, Inc., as Vice President & Head-US Oncology Business Unit, and Y-mAbs Therapeutics, Inc., as Chief Commercial Officer & Senior Vice President from 2022 to 2025.
Ms. Smith received her graduate degree from Purdue University.
Anciens postes connus de Sue Smith
| Sociétés | Poste | Fin |
|---|---|---|
| YMAS THER | Corporate Officer/Principal | 09/04/2025 |
Interlink Healthcare Communications | Corporate Officer/Principal | - |
EUSA Pharma, Inc.
 EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and researches pharmaceutical products | Corporate Officer/Principal | - |
Kyowa Kirin, Inc.
 Kyowa Kirin, Inc. Pharmaceuticals: OtherHealth Technology Kyowa Kirin, Inc. is a specialty pharmaceutical company dedicated to developing specialty medicines primarily for rare, serious, and underserved diseases. The company is based in Bedminster, NJ. The company focuses on therapeutic areas including bone and mineral diseases, hematologic malignancies and refractory hematologic diseases, nephrology, oncology, immunology, allergy, and neurology. Kyowa Kirin advances modalities such as next-generation antibody therapeutics, hematopoietic stem cell gene therapies, cell therapies, and proprietary antibody technologies. The company operates a network with subsidiaries and research facilities across multiple regions and is expanding manufacturing capacity to support late-stage biologic therapies. Kyowa Kirin emphasizes quality assurance, compliance, and patient safety throughout drug development, clinical trials, manufacturing, and commercialization. The company's clinical research prioritizes diversity and transparency, and they support patient communities and advocacy groups through research and educational initiatives. Partnerships with academic institutions, biotech, pharmaceutical companies, and patient organizations are central to their strategy. The company's portfolio includes medicines such as Crysvita, Poteligeo, Nourianz, and Komzifti, supported by patient assistance programs and expanded access policies. | Corporate Officer/Principal | - |
Formation de Sue Smith
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
2
Relations au 1er degré
5
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops and researches pharmaceutical products | Health Technology |
Purdue University
 Purdue University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Interlink Healthcare Communications | |
Y-mAbs Therapeutics, Inc.
 Y-mAbs Therapeutics, Inc. BiotechnologyHealth Technology Develops radioimmunotherapy and antibody-based oncology therapies for treating cancer | Health Technology |
Kyowa Kirin, Inc.
Kyowa Kirin, Inc. Pharmaceuticals: OtherHealth Technology Kyowa Kirin, Inc. is a specialty pharmaceutical company dedicated to developing specialty medicines primarily for rare, serious, and underserved diseases. The company is based in Bedminster, NJ. The company focuses on therapeutic areas including bone and mineral diseases, hematologic malignancies and refractory hematologic diseases, nephrology, oncology, immunology, allergy, and neurology. Kyowa Kirin advances modalities such as next-generation antibody therapeutics, hematopoietic stem cell gene therapies, cell therapies, and proprietary antibody technologies. The company operates a network with subsidiaries and research facilities across multiple regions and is expanding manufacturing capacity to support late-stage biologic therapies. Kyowa Kirin emphasizes quality assurance, compliance, and patient safety throughout drug development, clinical trials, manufacturing, and commercialization. The company's clinical research prioritizes diversity and transparency, and they support patient communities and advocacy groups through research and educational initiatives. Partnerships with academic institutions, biotech, pharmaceutical companies, and patient organizations are central to their strategy. The company's portfolio includes medicines such as Crysvita, Poteligeo, Nourianz, and Komzifti, supported by patient assistance programs and expanded access policies. | Health Technology |
